Effects of exercise training on cardiovascular risk factors in kidney transplant recipients: a systematic review and meta-analysis

Gang Chen\textsuperscript{a}, Liu Gao\textsuperscript{b} and Xuemei Li\textsuperscript{a}

\textsuperscript{a}Department of Nephrology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Science, Beijing, China; \textsuperscript{b}Department of Endocrinology, The Third Hospital of Hebei Medical University, Key Orthopaedic Biomechanics Laboratory of Hebei Province, Shijiazhuang, China

\section*{ABSTRACT}
\textbf{Background:} Whether exercise can improve cardiovascular health in kidney transplant recipients (KTRs) is unclear. Therefore, we performed a systematic review of the effects of exercise on cardiovascular risk factors in this population setting.

\textbf{Methods:} Randomized control trials (RCTs) evaluating the impact of exercise on major clinical outcomes in KTRs were identified by searches in Cochrane CENTRAL, PubMed, EMBASE, OVID and CBM updated to December 2018. The main outcomes of interest were blood pressure, lipid profile, blood glucose level, arterial stiffness, body weight, body mass index, exercise tolerance (VO\textsubscript{2} peak) and quality of life (QOL).

\textbf{Results:} After screening 445 studies in the database, we included 12 RCTs in the review and 11 RCTs for further qualitative analysis. The results indicate a significant improvement in small arterial stiffness \[\text{mean difference (MD): } -1.14, 95\% \text{ confidence interval (CI): } -2.19-0.08, p = .03\], VO\textsubscript{2} peak (MD: 2.25, 95\% CI: 0.54–3.69, \(p = .01\)), and QOL (MD: 12.87, 95\% CI: 6.80–18.94, \(p < .01\)) after exercise intervention in KTRs. However, there is no evidence for an improvement in blood pressure, lipid profile, blood glucose level, kidney function, body weight or body mass index.

\textbf{Conclusion:} Exercise intervention in KTRs improves arterial stiffness but does not consistently contribute to the modification of other CVD risk factors like hypertension, dyslipidemia, hyperglycemia, decreased kidney function and obesity. Exercise also improves exercise tolerance and QOL in KTRs.

\section*{Introduction}
Kidney transplantation (KTx) is the most desired renal replacement therapy for patients with end-stage renal disease (ESRD), with salutary effects on quality of life (QOL) \cite{1} and overall survival \cite{2} compared to dialysis. However, cardiovascular disease (CVD) remains one of the leading causes of death in kidney transplant recipients (KTRs), accounting for 17\% \cite{3} of total deaths, and KTRs have an overall mortality rate at least 5–10-fold greater than the general population \cite{4}.

Metabolic syndrome is highly prevalent after KTx, and preexistent comorbidities like hypertension, diabetes and hyperlipidemia continue to be well-recognized contributors to CVD in these patients. Further, the common immunosuppressive choices after KTx also contribute to the burden of CVD risk factors: corticosteroids tend to promote metabolic syndrome due to their antimitabolic effects; cyclosporine is associated with hypertension and hyperlipidemia while tacrolimus is related with insulin resistance and post-transplant diabetes \cite{5}.

Exercise is an attractive option for addressing many of the underlying CVD risk factors in KTRs. However, KTRs are at risk for reduced physical fitness due to physical limitation \cite{6}, medical comorbid conditions \cite{6–8}, skeletal muscle atrophy \cite{8}, depression \cite{8}, fatigue \cite{6} and lack of motivation \cite{7}. Although the cardiovascular benefits of physical activity in the general population have been confirmed in many studies, only a paucity of studies with conflicting results has been performed among KTRs \cite{9–11}. Thus, it is unclear whether exercise is an effective approach to reducing the risk of
CVD in KTRs, and KTRs remain a neglected population concerning exercise recommendations in the 2012 KDIGO (Kidney Disease: Improving Global Outcomes) guidelines [12].

The first meta-analysis of exercise in solid organ transplant recipients, published in 2013, only included 2 randomized control trials (RCT) for KTx [4]. Several newer trials [11,13–18] have been subsequently reported. The solitary meta-analysis on exercise efficacy in KTRs [19] focused only on publications from PubMed and Ichushi, a Japanese medical database; further, this analysis focused on the impact of exercise on exercise performance and QOL, without a specific examination of other CVD risk factors or components of the metabolic syndrome. Here, we undertook a systematic review and meta-analysis of all RCTs with the goal to capture all the available evidence examining exercise and KTx to establish the influence and effect size of various forms of regular exercise training on major clinical outcomes associated with cardiovascular health.

Methods

Data sources and selection criteria

The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) statement was followed in the conduct of this study [20]. We combined the results from searches of the Cochrane Central Register of Controlled Trials (CENTRAL; from start to December 2018), PubMed (from start to December 2018), EMBASE (from 1980 to December 2018), OVID (from 1993 to December 2018), and China Biology Medicine (CBM, from 1978 to December 2018). For this study, we used the following terms in the search strategy: exercise, physical activity, physical exercise, aerobic exercise, exercise training, isometric exercise, acute exercise, exercise therapy, physical exertion, exercise movement techniques, sports, physical fitness, kidney transplantation, renal transplantation, kidney grafting, and controlled clinical trial (for more details on the search strategy, please see Supplement S-1).

We included prospective RCTs that evaluated the efficacy of regular exercise training on various clinical outcomes in KTRs compared with controls without exercise.

Data extraction and quality assessment

Data from included studies were scrutinized and extracted by both authors (GC and LG) independently. The Cochrane Data Extraction and Assessment Form were used to explore the research eligibility and decide whether to include the study. Study quality was judged by selection bias, detection bias, attrition bias and completeness of follow-up. Any disagreement about the extracted data and quality assessment was reevaluated by the third author (Dr. Xuemei Li).

Statistical analysis

According to Cochrane handbook 5-1, the quantitative evaluation was based on the standardized differences between mean values in the intervention and control groups by the Inverse-variance method using RevMan 5.3 (Cochrane, Copenhagen, Denmark). We converted the data in different studies into international units for further meta-analysis. If clinical outcomes were measured more than once in a study, we selected the data closer in time between different studies. We used the model of random effects in RevMan after we assessed the clinical and methodological quality of the RCTs and considered there was heterogeneity among the different studies (Supplement S-2). A p value <.05 was considered statistically significant.

Heterogeneity between RCTs was analyzed by Q test of n – 1 df and p < .05 was considered statistically significant. The I² parameter was used to quantify any inconsistency.

Results

Search results

We extracted a total of 445 research papers from CENTRAL (n = 55), PubMed (n = 207), EMBASE (n = 125), OVID (n = 42) and CBM (n = 16) during the first screen through the databases. One-hundred twenty-two duplications were filtered, and 262 more studies were excluded after review of their titles and abstracts. The two authors (GC and LG) independently inspected the full-text of the 49 remaining references and agreed on including 12 RCTs in this study (Figure 1). The characteristics of the included studies are shown in Table 1. For further qualitative analysis, we extracted data from 11 RCTs and excluded 1 study [17] as it only measured bone mineral density as the primary outcome. Of the 11 RCTs for meta-analysis, aerobic training alone was performed in 2 trials [10,21], resistance training monotherapy was performed in 2 trials [14,16], 6 trials combined aerobic and resistance methods [11,13,15,18,23,24], and 1 trial did not specify the exercise type [22]. For exercise intensity, most trials adopted more than 60% maximum heart rate or maximal oxygen uptake, but 3 studies did not report details on exercise intensity [14,18,22]. Most trials provided a 30–60 min
exercise session for 2–4 times per week. In terms of the total intervention period, most trials ranged from 10 weeks to 6 months. Only 1 trial designed the intervention for 4–5 weeks [22] while 3 trials extended the duration to 12 months [10,14,21]. For the controlled arms, patients maintained usual care.

**Risk of bias in included trials**

All participants were randomly assigned in the included trials. The methods of randomization were reported in 7/12 (58.3%) of the trials. Allocation concealment was adequate in 6/12 (50.0%) but unclear in the other 50%. Masked outcome assessment was only done in 2/12 (16.7%) of the studies. Blinded administration in these RCTs was not feasible and none of the participants were blinded to the interventions in any of the studies. The intervention compliance was evaluated in 6/12 (50%) of the trials. Only 2/12 (16.7%) of the trials used intention-to-treat analysis. The detailed clinical and methodological quality assessment of individual trials is available in supplementary (Supplement S-2).

**Study outcomes**

We aimed to evaluate the blood pressure (BP), lipid profile, blood glucose level, arterial stiffness, kidney function, body weight and body mass index (BMI), all important indicators of cardiovascular health. The exercise tolerance (VO₂ peak) and QOL were also included in quantitative analysis.

**Blood pressure**

Five trials investigated a total of 199 participants to judge the effects of exercise on BP [10,11,16,18,24], using different types of exercise training. Both the systolic and diastolic BP were measured during resting.
| Studies          | Country | Mean age (SD), years | Number, n | Exercise intervention                                      | Duration | Intensity of intervention                                      | Control       | Outcome measurements                                                                 | Primary outcomes                                                                 |
|------------------|---------|----------------------|-----------|----------------------------------------------------------|----------|-----------------------------------------------------------------|---------------|-------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| Painter et al.   | US      | Ex: 39.7 ± 12.6      | 54        | Home-based exercise (walking or cycling) of at least 30 min per section, 4 times per week | 12 months| Initially 60–65% of maximal HR, gradually increased to 75–80% of maximal HR | Routine care  | VO₂ peak, quadriceps muscle strength, body composition, QOL                         | Exercise results in higher levels of measured and self-reported physical functioning but does not affect body composition. |
| Painter et al.   | US      | Ex: 39.7 (12.6)      | 51        | Home-based exercise (walking or cycling) of at least 30 min per section, 4 times per week | 12 months| Initially 60–65% of maximal heart rate, gradually increased to 75–80% of maximal HR | Routine care  | Lipids, BP, maximum METs, BMI                                                        | Exercise alone does not reduce CVD risk during the first year after transplantation. |
| Juskowa et al.   | Poland  | Ex: 43.75 (12.2)     | 32        | Tailored exercises 15–30 min every other day assisted by physiotherapists | 4–5 weeks| No data                                                        | Routine care  | Biochemical markers of atherosclerosis, muscle strength, pulmonary function       | Exercise after KTx produces no significant effects on the markers of atherosclerosis |
| Min et al.       | China   | Ex: 35.8 (13.5)      | 28        | Treadmill and resistance training of 45–60 min per section, 3 times a week | 6 months | 70–85% of maximal HR                                         | Routine care  | QOL                                                                                | Exercise has beneficial effects on the life quality of KTRs.                      |
| Kouidi et al.    | Greece  | Ex: 52.1 (5.6)       | 11        | 30–40 min aerobic exercise followed by 10–30 min of strengthening exercises, 4 times a week | 6 months | 50–75% VO₂ peak or 65–85% maximal HR                          | Routine care  | VO₂ peak, tilt test for the evaluation of baroreflex, 24-h Holter for heart rate variability | Exercise increases cardiorespiratory fitness.                                     |
| Pooranfar et al. | Iran    | No data              | 29        | A combination of aerobic and resistance exercises 60–90 min sessions per week | 10 weeks | 40–70% maximum HR and resistive exercise with 45%–65% of maximum frequency | Routine care  | Sleep quality, lipid profiles                                                      | Exercise improves the quality and quantity of sleep; ameliorate lipid profile.   |
| Riess et al.     | Canada  | Ex: 56.9 (12.2)      | 16        | Endurance (3 days/week) and strength training (2 days/week) for 30–60 min per session. | 12 weeks | 60–80% VO₂ peak; maintain Borg score 11–13                     | Routine care  | VO₂ peak, leg strength, 24-hour blood pressure, arterial compliance, QOL, CVD risk score | Exercise improves peak exercise aerobic capacity and cardiac output, muscle strength and QOL. |
| Tzvetanov et al. | US      | Ex: 46 (6.9)         | 9         | Individual physical training using low-impact, low-repetition, resistance- | 12 months| No data                                                        | Routine care  | Body composition, PWV, IMT, weight lifting capacity, GFR, lipid profiles, glucose | Exercise can improve body composition, kidney function, quality of life.           |
|                  |         | Con: 45 (19)         |           |                                                          |          |                                                                |               |                                                                                     |                                                                                   |
| Studies                      | Country | Mean age (SD), years | Number, n | Exercise intervention                                                                 | Duration | Intensity of intervention | Control     | Outcome measurements                                                                 | Primary outcomes                                                                 |
|-----------------------------|---------|----------------------|-----------|---------------------------------------------------------------------------------------|----------|--------------------------|-------------|--------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| Greenwood et al. [15]       | UK      | Ex: aerobic training 53.9 (10.7), resistance training 54.6 (10.6) Con: 49.5 (10.6) | Ex: aerobic training 13, resistance training 13. Con: 20 | Exercise based weight training for 1-hour, 2/week. Aerobic: a tailored training program for 60 min session, 3 times per week. Resistance: 60 min muscle training, 3 times a week. | 12 weeks  | Borg score 13–15           | Routine care | VO₂ peak, PWV, quadriceps muscle strength, sit-to-stand 60 tests, inflammatory bio-markers, kidney function, QOL | Exercise improves PWV, VO₂ peak, and muscle strength. |
| Karelis et al. [16]         | Canada  | Ex: 45.3 (14) Con: 39.4 (8) | Ex: 10 Con: 10 | Individual total body resistance training of 45–60 min, 3 times per week              | 16 weeks | 80% of the 1-repetition maximum | Routine care | VO₂ peak, muscle strength, BP, lipid profile, OGTT, body composition, cardio-metabolic risk factors, and QOL | Exercise training improves strength and QOL, but no change in CVD risk factors. |
| O'Connor et al. [18]        | UK      | Ex: aerobic training 53.9 (10.7), resistance training 54.6 (10.6) Con: 49.5 (10.6) | Ex: aerobic training 13, resistance training 13; Con: 20 | Twice-weekly supervised, and once-weekly home-based, individually tailored exercise training for 12 weeks. Self-managed exercise continued after that. | 9 months  | No data                   | Routine care | PWV, VO₂, peak, blood pressure, and body weight | Resistance exercise improves PWV. Aerobic exercise improves VO₂2 peak. No difference in blood pressure or body weight between groups. |
| Eatamadololama et al. [17]  | Iran    | Ex: 27.4 (17.36) Con: 36.0 (4.35) | Ex: 12 Con: 12 | Supervised upper and lower body resistance training of 80 min, twice per week.     | 12 weeks | Initially 50% of one repetition maximum, and increase 5–10% for the next sessions | Routine care | BMD                                                                                 | Exercise improves long bone mineral density.                                     |

Ex: Exercise; Con: Control; US: United States; UK: United Kingdom; HR: Heart rate; BP: Blood pressure; VO₂ peak: Maximal oxygen uptake; QOL: Quality of life; MET: Maximum exercise tolerance; BMI: Body mass index; BMD: Bone mineral density; CVD: Cardiovascular disease; KTx: Kidney transplantation; KTRs: Kidney transplant recipients; PWV: Pulmonary wave velocity; IMT: Intima-media thickness; GFR: glomerular filtration rate; OGTT: Oral glucose tolerance test.

Borg score: the Borg rating of perceived exertion scale applied to estimate exercise intensity [25].
Data showed that exercise had no effects on either systolic [mean difference (MD) 1.67; 95% confidence interval (CI): 2.17 – 5.51; \( p = .39 \)] or diastolic BP (MD: 0.65, 95% CI: 4.02 – 5.32, \( p = .78 \)) (Figure 2).

**Lipid profile**

Three RCTs [13,16,22] assessed lipid profiles including total cholesterol (TC), low-density lipoprotein (LDL) cholesterol, and triglyceride (TG) levels and an additional 2 trials [10,11] examined only TC changes. The referred trials represented aerobic training, resistance training or a combination of both. After the qualitative analysis for totally 261 patients, we found no significant benefits in overall lipid profile after exercise intervention (MD: 0.03, 95% CI: 0.09 – 0.15, \( p = .62 \)). In subgroup analysis, TC (\( p = .15 \)), LDL cholesterol (\( p = .83 \)) and TG (\( p = .82 \)) were not ameliorated by exercise (Figure 3).

**Blood glucose**

Two trials have measured blood glucose changes after exercise intervention in KTRs [14,16]. Karellis et al. employed resistance training in the intervention group for 16 weeks and found no significant changes in either fasting glucose or glucose tolerance [16]. Another study found neutral results in fasting glucose after a 12-month intervention, but the author did not provide available data for further interpretation [14]. As a result, qualitative analysis concerning blood glucose was not feasible.

**Arterial stiffness**

Small arterial compliance was examined in 2 trials by either pulmonary wave velocity (PWV) [15] or computerized arterial pulse waveform analysis [11]. Both RCTs measured the clinical outcomes after 12-week intervention. A qualitative analysis including 64 patients showed a consistent improvement in small arterial stiffness after exercise intervention (MD: \(-1.14 \), 95% CI: \(-2.19 \) – \(-0.08 \), \( p = .03 \)) (Figure 4). In another study, Tzvetanov et al. [14] measured PWV in the intervention group and found a substantial decrease from 9.4 ± 6.3 m/s at baseline to 7.7 ± 1.7 m/s at 12 months, but no data could be obtained for the control group. For large artery compliance, Riess et al. [11] reported no significant modification after exercise therapy (\( p = .95 \)).

**Kidney function**

To evaluate the impact of exercise on allograft function in KTRs, we included two trials [14,15] which calculated eGFR in a total of 22 subjects in the exercise group and 28 controls. The intervention consisted of 12 months of resistance training [14] or regimens of aerobic or resistance training for 12 weeks [15]. The qualitative evaluation revealed that exercise training was not associated with an improvement in kidney function (MD: 2.60, 95% CI: \(-12.88 \) – \(-13.09 \), \( p = .74 \)). Three trials [14,21,22]...
mentioned serum creatinine (SCr) measurements before and after the intervention, but the baseline SCr in one RCT [22] was obtained before KTx. We included the other 2 trials with baseline SCr after KTx in a meta-analysis and found a significant decrease in SCr after exercise intervention (MD: −33.70, 95% CI: −64.97 to −2.44, p = .03) (Figure 5).

**Body composition**

Body weight was measured in 3 RCTs [15,16,18] and BMI was calculated in 4 trials [10,15,16,18]. The intervention consisted of aerobic training, resistance training or the combination, and ranged from 12 weeks to 12 months. The effects of exercise on BW (MD: −2.02, 95% CI: −8.24 to 4.20, p = .52) or BMI (MD: 0.12, 95% CI: −1.52 to 1.77, p = .88) were not significant (Supplement S-3).

**Exercise tolerance**

Six RCTs analyzed VO₂ peak as an indicator of exercise tolerance [11,15,16,18,21,24]. To generate a qualitative synthesis, we excluded the trial by O’Connor et al. [18] as it was the long-term follow up of the same cohort data reported in Greenwood et al. [15]. The remaining 5
trials had a total of 202 patients and revealed a significant improvement in exercise capacity (MD: 2.25, 95% CI: 0.54–3.69, \( p =.01 \)) after aerobic training [21], resistance training [16] or combined method [11,15,24] over the course of 12 weeks–12 months (Figure 6).

QOL

QOL was mostly evaluated by the QOL short form (SF)-36 questionnaire in the included RCTs, with assessment of different dimensions like physical functioning [21,23], physical composite score [15,21], physical performance [21,23], social functioning [11,23] and mental health [11,15,23], as well as overall QOL score [11,16]. These trials employed different exercise types for both short and long-term intervention. Generally, exercise improved QOL in different aspects, with significant enhancement in social functioning (MD: 16.76, 95% CI: 2.16–31.37, \( p =.02 \)) and overall QOL scores (MD: 12.87, 95% CI: 6.80–18.94, \( p < .01 \)) (Supplementary S-3).

Discussion

This is the first quantitative meta-analysis interpreting the effects of exercise intervention on diverse cardiovascular risk factors in KTRs. Although discrepancy existed in exercise type and intervention time of the included studies, we found there was low heterogeneity in the analysis related to systolic BP, lipid profiles, and small arterial stiffness. Results of the present study indicate that exercise tolerance and QOL are significantly enhanced after the exercise intervention. However, the usefulness of exercise in amending traditional CVD risk factors such as hypertension, hyperlipidemia and hyperglycemia is questionable. Encouragingly, the recently recognized CVD risk factor arterial stiffness does appear to improve after exercise in KTRs.

Traditional CVD risk factors identified in population-based cohorts such as the Framingham Heart Study include age, sex, smoking status, systolic BP, TC, high-density lipoprotein cholesterol, left ventricular hypertrophy and diabetes; [26] the combination of these risk factors can be used to predict 10-year-risk for CVD [26]. A more recent version of the Framingham risk prediction strategy includes diastolic BP and LDL cholesterol as additional CVD risk factors [27]. A substantial body of evidence has demonstrated the benefits of exercise on BP [28,29], lipid profiles [30] and blood glucose [31,32]...
in the general population, highlighting a central role for exercise in the primary and secondary prevention of CVD. However, our meta-analysis shows that the benefit of exercise may not extend to KTRs, at least for several of these traditional risk factors. There are some possible explanations: (1) many traditional CVD risk factors are pathophysiologic determinants rooted in long-term unadjusted life habits and they cannot be easily attenuated with a relatively short-term exercise intervention; (2) the multiple pathological factors that contribute to the high rates of CVD in KTRs are too strong to overcome by the monotherapy of exercise, and may instead require a combinatorial approach with other lifestyle interventions; (3) KTRs still suffer from the residual effects of renal failure while the administration of steroids or calcineurin inhibitors reverses the benefits of exercise; and (4) to best appreciate the impact of exercise and its impact on CVD risk, changes in maintenance medications that might result from exercises, such as a reduction in antihypertensives and lipid-lowering therapy should also be considered. However, there was no extractable data in the included RCTs for this issue. To better design trials to judge the effects of exercise, the dosing and categories of these medications should be considered.

In contrast to a lack of effect on BP, lipid profiles, and fasting glucose, exercise does have a beneficial impact on arterial stiffness, even after intervention as short as 3 months. Arterial stiffness has emerged as an additional CVD risk factor [33,34] and a systematic review shows that the consideration of PWV can improve the prediction of CVD events [35]. Increased age, metabolic syndrome, and inflammation, risk factors enriched in the ESRD population, all contribute to arterial stiffening [36]. Some studies have shown that increased arterial stiffness in patients with chronic kidney disease increases the likelihood of progressive kidney loss and a substantial predisposition to CVD [37]. The qualitative analysis demonstrates that the addition of exercise can improve the artery stiffness in KTRs, in addition to the restore of kidney function.

It has also been recognized that the decreased level of kidney function is an independent CVD risk factor [38,39]. In our analysis, exercise therapy did not improve kidney function as assessed by eGFR. The two trials included in the qualitative analysis provided inconsistent results [14,15]. Greenwood et al. [15] found no improvement in eGFR whereas Tzvetanov et al. [14] found an increase in eGFR and lower Scr in the exercise group compared with control. We noticed that the latter one was a personalized rehabilitation program designed for obese KTRs. The explanations for the discrepancy may be personalized guidance in exercise or that obese patients benefit better in exercise.

Obesity, which exacerbates metabolic syndrome and inflammatory status, is an additional CVD risk factor [40,41]. The unchanged body weight and BMI after exercise intervention are somehow unexpected, especially in the trial targeted at obese KTRs for a 12-month long intervention [14]. However, the KTRs may improve their appetite and gain weight thanks to the depletion of uremic status after transplantation. It is possible that detailed body composition improves with exercise, without a measurable change in body weight or BMI, but data on the hip to waist ratio, %lean weight, etc. were not available for analysis. Alternatively, in the absence of simultaneous dietary guidance, patients might mistakenly adopt a high-calorie or a high-fat diet with increased activity and thus compromise the beneficial effects of exercise.

VO2 peak is an established method to determine cardiorespiratory function [15]. In our analysis, we included 3 more RCTs than the only previous meta-analysis of exercise in KTRs [19] and demonstrated a benefit of exercise in KTRs. We also examined more components of the QOL evaluation, again showing a benefit for exercise. Thus, independent of an effect on CVD risk factors, these results underscore a benefit for exercise in overall physical and mental wellbeing.

There are some limitations to our systematic review. First, the RCTs addressing this topic are of heterogeneous quality, and for several of the clinical outcomes of interest, the number of trials eligible for analysis is relatively small. Second, it was not feasible to conduct blinded RCTs by using exercise intervention and the compliance to the intervention was not evaluated in some studies, thus compromising the quality of the trials. Third, the majority of the RCTs included limited participants and conducted an intervention for no more than 6 months. Therefore, to better address the efficacy of exercise on CVD in KTRs, we would recommend further clinical studies to include more participants and to evaluate the long-term effects by using a certain type of exercises that could be easily quantified with the intervention intensity.

**Conclusion**

Our systematic review demonstrates that exercise in KTRs has a mixed impact on CVD risk profiles. It improves arterial stiffness, exercise tolerance and QOL, but does not significantly improve other key CVD risk factors such as hypertension, dyslipidemia, hyperglycemia, decreased kidney function and obesity.
Additional long-term RCTs examining a greater number of patients are needed to understand the effects of exercise on cardiovascular health in KTRs.

Acknowledgments

We are grateful to Dr. Eugene P. Rhee, MD, from Massachusetts General Hospital, for editing the English text of this manuscript and offering helpful comments on the discussion.

Disclosure statement

No potential conflict of interest was reported by the authors.

Funding

This work is supported by the Fundamental Research Funds for the Central Universities [grant number 3332018005].

ORCID

Gang Chen http://orcid.org/0000-0002-5314-4249
Liu Gao https://orcid.org/0000-0002-9263-5614

References

[1] Jansz TT, Bonenkamp AA, Boereboom FTJ, et al. Health-related quality of life compared between kidney transplantation and nocturnal hemodialysis. PloS One. 2018;13:e0204405.
[2] Schold JD, Buccini LD, Goldfarb DA, et al. Association between kidney transplant center performance and the survival benefit of transplantation versus dialysis. CjASN. 2014;9:1773–1780.
[3] Neale J, Smith AC. Cardiovascular risk factors following renal transplant. Wjt. 2015;5:183–195.
[4] Didsbury M, McGee RG, Tong A, et al. Exercise training in solid organ transplant recipients: a systematic review and meta-analysis. Transplantation. 2013;95:679–687.
[5] Shivaswamy V, Boerner B, Larsen J. Post-transplant diabetes mellitus: causes, treatment, and impact on outcomes. Endocr Rev. 2016;37:37–61.
[6] van Adrichem EJ, van de Zande SC, Dekker R, et al. Perceived barriers to and facilitators of physical activity in recipients of solid organ transplantation, a qualitative study. PLoS One. 2016;11:e0162725.
[7] Gordon EJ, Prohaska TR, Gallant M, et al. Self-care strategies and barriers among kidney transplant recipients: a qualitative study. Chronic Illn. 2009;5:75–91.
[8] Painter P. Physical functioning in end-stage renal disease patients: update 2005. Hemodial Int. 2005;9:218–235.
[9] Zelle DM, Corpeleijn E, Stolk RP, et al. Low physical activity and risk of cardiovascular and all-cause mortality in renal transplant recipients. CjASN. 2011;6:898–905.
[10] Painter PL, Hector L, Ray K, et al. Effects of exercise training on coronary heart disease risk factors in renal transplant recipients. Am J Kidney Dis. 2003;42:362–369.
[11] Riess KJ, Haykowsky M, Lawrance R, et al. Exercise training improves aerobic capacity, muscle strength, and quality of life in renal transplant recipients. Appl Physiol Nutr Metab. 2014;39:566–571.
[12] KDIGO. Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Supplements. 2012;2013:1–150.
[13] Pooranfar S, Shakoor E, Shafahi M, et al. The effect of exercise training on quality and quantity of sleep and lipid profile in renal transplant patients: a randomized clinical trial. Int J Organ Transplant Med. 2014;5:157–165.
[14] Tzvetanov I, West-Thielke P, D’Amico G, et al. A novel and personalized rehabilitation program for obese kidney transplant recipients. Transplant Proc. 2014;46:3431–3437.
[15] Greenwood S, Koufaki P, Mercer T, et al. Aerobic or resistance training and pulse wave velocity in kidney transplant recipients: a 12-week pilot randomized controlled trial (the Exercise in Renal Transplant [ExeRT] Trial). Am J Kidney Dis. 2015;66:689–698.
[16] Karelis AD, Hébert MJ, Rabasa-Lhoret R, et al. Impact of resistance training on factors involved in the development of new-onset diabetes after transplantation in renal transplant recipients: an open randomized pilot study. Can J Diabetes. 2016;40:382–388.
[17] Eatmenadololama A, Karimi MT, Rahnama N, et al. Resistance exercise training restores bone mineral density in renal transplant recipients. Ccmbm. 2017;14:157–160.
[18] O’Connor EM, Koufaki P, Mercer TH, et al. Long-term pulse wave velocity outcomes with aerobic and resistance training in kidney transplant recipients - a pilot randomised controlled trial. PLoS One. 2017;12:e0171063.
[19] Oguchi H, Tsujita M, Yazawa M, et al. The efficacy of exercise training in kidney transplant recipients: a meta-analysis and systematic review. Clin Exp Nephrol. 2019;23:275–284.
[20] Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Bmj. 2009;339:b2700.
[21] Painter PL, Hector L, Ray K, et al. A randomized trial of exercise training after renal transplantation. Transplantation. 2002;74:42–48.
[22] Juskowa J, Lewandowska M, Bartmiejczyk I, et al. Physical rehabilitation and risk of atherosclerosis after successful kidney transplantation. Transplant Proceed. 2006;38:157–160.
[23] Min M, Zuo F, Wang L, et al. Effects of physical exercise on life quality of kidney transplant recipients. Chinese J Tissue Eng Res. 2012;16:5733–5736.
[24] Kouidi E, Vergoulas G, Anifanti M, et al. A randomized controlled trial of exercise training on cardiovascular and autonomic function among renal transplant recipients. Nephrol Dial Transplant. 2013;28:1294–1305.
Coquart JB, Garcin M, Parfitt G, et al. Prediction of maximal or peak oxygen uptake from ratings of perceived exertion. Sports Med. 2014;44:563–578.

Anderson KM, Wilson PW, Odell PM, et al. An updated coronary risk profile. A statement for health professionals. Circulation. 1991;83:356–362.

Wilson PWF, D’Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–1847.

Whelton SP, Chin A, Xin X, et al. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med. 2002;136:493–503.

Cornelissen VA, Fagard RH. Effects of endurance training on blood pressure, blood pressure-regulating mechanisms, and cardiovascular risk factors. Hypertension. 2005;46:667–675.

Tambalis K, Panagiotakos DB, Kavouras SA, et al. Responses of blood lipids to aerobic, resistance, and combined aerobic with resistance exercise training: a systematic review of current evidence. Angiology. 2009;60:614–632.

Sigal RJ, Kenny GP, Boule NG, et al. Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: a randomized trial. Ann Intern Med. 2007;147:357–369.

Bacchi E, Negri C, Zanolin ME, et al. Metabolic effects of aerobic training and resistance training in type 2 diabetic subjects: a randomized controlled trial (the RAED2 study). Diabetes Care. 2012;35:676–682.

Palombo C, Kozakova M. Arterial stiffness, atherosclerosis and cardiovascular risk: pathophysiologic mechanisms and emerging clinical indications. Vascul Pharmacol. 2016;77:1–7.

Vlachopoulos C, Aznaouridis K, Stefanadis C. Aortic stiffness for cardiovascular risk prediction: just measure it, just do it! J Am Coll Cardiol. 2014;63:647–649.

Ben-Shlomo Y, Spears M, Boustred C, et al. Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. J Am Coll Cardiol. 2014;63:636–646.

Sun Z. Aging, arterial stiffness, and hypertension. Hypertension. 2015;65:252–256.

Townsend RR. Arterial stiffness and chronic kidney disease: lessons from the Chronic Renal Insufficiency Cohort study. Curr Opin Nephrol Hypertens. 2015;24:47–53.

Thompson S, James M, Wiebe N, et al. Cause of death in patients with reduced kidney function. J Am Soc Nephrol. 2015;26:2504–2511.

Manjunath G, Tighiouart H, Ibrahim H, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol. 2003;41:47–55.

Ortega FB, Lavie CJ, Blair SN. Obesity and cardiovascular disease. Circ Res. 2016;118:1752–1770.

Bastien M, Poirier P, Lemieux I, et al. Overview of epidemiology and contribution of obesity to cardiovascular disease. Prog Cardiovasc Dis. 2014;56:369–381.